mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Current Jobs

Key Account Manager
Location: South West & Wales

Brand Manager
Location: Surrey

Novartis gains rights to blood disorder therapies

Posted on 26/11/2009 in Pharmaceutical Company Product News

Novartis announced this week that it has received the rights to two oral targeted investigational therapies intended for use in patients with life-threatening blood disorders and cancers.

These are INCB18424 - which is in phase III development as a first-in-class treatment for myelofibrosis ? and cMET inhibitor INCB28060, which targets tumour invasion and drug resistance in gastric, kidney and lung cancers.

An upfront payment of $150 million (90 million pounds) and an initial milestone of $60 million will be offered by Novartis as part of the procedure.

David Epstein, president and chief executive of Novartis Oncology and Novartis Molecular Diagnostics, commented: "This agreement leverages these two promising investigational drugs with Novartis Oncology's global development and commercialisation expertise and our wide range of multi-targeted approaches to cancer treatment."

This news comes after Novartis announced last week that that just half of its vaccine dose for H1N1 influenza could fully protect an individual from the virus.

Other news stories from 26/11/2009

Read more in the Zenopa News Archive

How this news is generated

Alessia
Account Manager
for this opportunity

01494 818 010
(Mon to Fri 0830 to 1800 hours)
alessia@zenopa.com

Latest News

Novartis hosts international research seminar

Novartis becomes majority owner of Alcon

Novartis awards prizes for immunology research

Novartis and Quark to co-develop new RNAi-based drug

Novartis launches new COPD treatment in UK

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use